US20020128174A1 - Vp22 proteins and uses thereof - Google Patents

Vp22 proteins and uses thereof Download PDF

Info

Publication number
US20020128174A1
US20020128174A1 US09/381,211 US38121199A US2002128174A1 US 20020128174 A1 US20020128174 A1 US 20020128174A1 US 38121199 A US38121199 A US 38121199A US 2002128174 A1 US2002128174 A1 US 2002128174A1
Authority
US
United States
Prior art keywords
protein
cell
cells
microtubules
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/381,211
Other languages
English (en)
Inventor
Gillian Daphne Elliott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phogen Ltd
Original Assignee
Phogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phogen Ltd filed Critical Phogen Ltd
Assigned to PHOGEN LIMITED reassignment PHOGEN LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ELLIOTT, GILLIAN DAPHNE
Publication of US20020128174A1 publication Critical patent/US20020128174A1/en
Priority to US10/617,910 priority Critical patent/US7067632B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • This invention relates to uses of VP22 proteins (and of its variants) e.g. for modifying cell structure and cell division.
  • the invention also relates to variants of VP22 proteins, e.g. active portions and derivatives.
  • the invention relates further to compositions comprising VP22 proteins and to methods and materials for producing them, including without limitation polynucleotides and recombinant cells and vectors encoding them.
  • HSV 1 herpes simplex virus type 1
  • VP22 Elliott et al, J. Gen. Virol., 73:723-6
  • HSV tegument a compartment of the virion located outside the capsid and inside the envelope and composed of at least 10 or more additional virus polypeptides.
  • VP22 has a molecular weight of 32 kD, is very basic and is modified by phosphorylation and nucleotidylation in the infected cell.
  • VP22 has more than one role to perform during infection—initially as a functional protein during viral gene expression, and subsequently as a structural component of the virion during virus assembly. As regards the former, some evidence exists to suggest that VP22 can bind specifically to HSV 1 DNA.
  • Applications of the transport property of VP22 disclosed in WO 97/05265 include associating molecules with VP22 so that they are transported to a target population of cells, either by expression of VP22, or an active fragment thereof, and the associated molecule as a fusion protein in some of the cells in the population, or by coupling VP22, or an active fragment thereof, to the associated molecule and exposing a population of cells to the VP22 complex directly.
  • the present invention is related to a new finding that herpesviral VP22 protein, particularly for example the VP22 protein of HSV1, has the property of binding to microtubules in cells.
  • the present invention provides uses of VP22 that exploit this property, and further relates to variant VP22 molecules lacking or modified for reduction in potency of this property, and to their uses. It has been observed in particular, that in cells in which VP22 is expressed, the VP22 protein that is not secreted binds to cellular microtubules (MTs) in a cytoplasmic filamentous pattern.
  • MTs microtubules
  • VP22 can be employed in applications such as stabilising MTs and retarding cell growth, in the delivery of MT binding drugs, and in gene or protein delivery in which MT associated transport is required.
  • VP22 means a protein which has sequence homology with VP22 and has a microtubule binding function of VP22.
  • the invention provides use of herpesviral VP22 protein or of another protein which has sequence homology with VP22 and a microtubule binding function of VP22, or a derivative thereof, to stabilise animal cellular microtubules, and also provides methods of retarding or arresting growth and cell division, or of inducing cell death, of an animal cell which comprises exposing said cell to herpesviral VP22 protein or of another protein which has sequence homology with VP22 and a microtubule binding function of VP22, or a derivative thereof, in an amount effective to stabilise the microtubules of said cell.
  • VP22 protein or of another protein which has sequence homology with VP22 and a microtubule binding function of VP22, or a derivative thereof, in an effective amount to retard or inhibit the cell division of animal cells, e.g. in antineoplastically effective amounts to retard or inhibit the cell division of neoplastic cells in vitro or in vivo, e.g. melanoma cells, ovarian cancer cells, or leukemia cells among others.
  • Further examples of such use include use in amounts effective to inhibit cell proliferation and/or induce cell death of other animal cells, e.g. cells of protozoal parasites, e.g. in vitro or in vivo.
  • herpesviral VP22 proteins and other proteins with sequence homology with VP22 and a microtubule binding function of VP22, or derivative thereof can be used for delivery also of other microtubule-binding drugs, e.g. taxol or its derivatives, or colchicine.
  • the invention also provides use of herpesviral VP22 protein or of another protein which has sequence homology with VP22 and a microtubule binding function of VP22, or a derivative thereof, in the preparation of medicaments for delivery of substances to cell microtubules.
  • the derivative can be a coupling product comprising VP22 and another substance to be delivered to the microtubules.
  • VP22 can be used, e.g. in amounts effective to stabilise microtubules and/or to enhance their degree of acetylation (as described below) and/or to inhibit the cells from progressing through the G2 and M phases of the cell cycle, not only for pharmaceutical effect but also as reagents in-vitro to study microtubules or the cell cycle particularly at cell division.
  • a derivatives can be a fusion protein between VP22 and an indicator protein, e.g. a fusion protein between VP22 and green fluorescent protein.
  • the initial localisation of the determinant in VP22 responsible for binding to the microtubules makes it possible to use protein engineering to provide and make variants of herpesviral VP22 proteins that have a reduced tendency to bind to microtubules, or even substantially lack this property altogether, but retain the useful transport property of VP22.
  • VP22 means a protein which has the transport property and function described in specification WO 97/05265.
  • MTs are polymers of heterodimers composed of alpha-and beta-tubulin. They form networks within the cytoplasm and perform several functions for the cell, including the trafficking of organelles and vesicles, the movement of chromosomes during mitosis, and the general organisation of the cytoplasm and maintenance of cell architecture.
  • MTs are dynamic structures, which grow from a central MT organising centre (MTOC) out towards the periphery of the cell. These dynamics are important during cell division when the MTs depolymerise to form the spindle poles. As such, inhibition of MT depolymerisation can lead to retarded cell division. Therefore, they are targets for the treatment of proliferative disorders such as cancer.
  • MTOC MT organising centre
  • the invention provides methods and compositions for treating cells with a VP22 protein, thereby to stabilise the microtubules in said cells: the invention extends to methods of using VP22 in the manufacture of such compositions.
  • the VP22 protein can be used in the form of a coupling product with an indicator protein such as green fluorescent protein (described in WO 97/05265), and such a coupling product can be used for example as a tool for the microscopic examination of MT reorganisation in the cell cycle in live cells in vitro.
  • an indicator protein such as green fluorescent protein (described in WO 97/05265)
  • the present invention also provides the use of VP22, or an active portion or derivative thereof having the property of binding to microtubules, in the preparation of a medicament for stabilising microtubules in a population of cells.
  • This stabilisation can have the effect of directly retarding the growth of cells, and be useful in the treatment of proliferative disorders such as cancer.
  • the stabilisation of the microtubules against agents that depolymerise microtubules can be used to protect a portion of a population of cells from the effects of these agents, e.g. while diseased cells in the population are treated.
  • agents include nocodazole, colecemid (used in anti-fungal therapy) or vinblastine and derivatives thereof (used in anti-cancer therapy).
  • the known transport property of VP22 can be used to deliver the VP22 to the cells to stabilise the MTs, either by expressing nucleic acid encoding VP22 in at least a portion of the cells in the population or by directly exposing the cells to VP22 protein.
  • the present invention provides the use of VP22, or an active portion or derivative thereof having the property of binding to microtubules in the preparation of a medicament for delivery of a substance to the microtubules, e.g. by the use of a coupling product comprising VP22 and the substance to be delivered to the MTs.
  • VP22 can be targetted to a cell in conjunction with a further MT binding substance such as taxol or a derivative thereof, or colchicine. VP22 can also be used to deliver the further MT binding substance to the MTs, helping to enhance the activity of the substance and/or to allow a reduced dose of the substance to be used in the treatment of a patient.
  • a further MT binding substance such as taxol or a derivative thereof, or colchicine.
  • VP22 can also be used to deliver the further MT binding substance to the MTs, helping to enhance the activity of the substance and/or to allow a reduced dose of the substance to be used in the treatment of a patient.
  • chemotherapeutic agents such as a taxol or derivatives thereof which retard cell growth by binding to MTs. Some of these substances can have severe side effects, thus enhancing the activity of the substances and/or reducing the dose required in a given situation can be useful.
  • one aspect of the invention provides a coupling product between a VP22 protein and a therapeutic agent that affects assembly or disassembly of MTs.
  • a coupling product between VP22 and a taxol or related compound which can be made using per se known chemical coupling methods.
  • a further example is a coupling product between a VP22 protein and colchicine.
  • the invention also extends to the use of such coupling products. Amongst the uses of these particular coupling products are that they can be useful as tools to study the cell cycle particularly at cell division.
  • the invention also provides uses of VP22 proteins, and of their variants which possess MT binding function, in ways analogous to the uses known for MT binding substances such as taxol, and the resulting materials can be used if desired in conjunction with other MT binding substances.
  • Delivery of VP22 to target cells for the purposes described herein can if desired be achieved through the use of corresponding gene vectors as described in WO 97/05265, and the uses of such vectors including recombinant virus vectors, and nonviral vectors such as lipofection or transfection by naked DNA, such as herpesviral vectors carrying modified forms of VP22, are within the scope of the ivnention.
  • Taxol and related compounds, and their uses adaptable by and applicable to this invention include for example the substances and derivatives related to taxol and their uses, as described in WO 89/08453 and U.S. Pat. No. 4,942,184 (R Haugwitz et al: US Secretary of State of Commerce) (describing water-soluble derivatives of taxol and their cytotoxic and anti-neoplastic uses); WO 90/10443 (V Stella et al: Univ Kansas); EP 0 537 905, EP 0 473 326, and EP 0 505 047 (DGI guitarist et at: Virginia Tech); and EP 0 524 093, WO 93/02065 (J D Bourzat et al: Rhone Poulenc Rorer S A); and EP 0 558 959 and U.S. Pat. No. 5,272,171 (Y Uedai et at: Bristol Myers Squibb) (describing derivatives of taxol and uses for anti-
  • the delivery of the MT binding materials to MTs can be a step in the transport of the substance to other types of cells.
  • MT associated transport is believed to be involved in the neuronal transport of substances.
  • transport of the substance to such cells can be achieved by virtue of the VP22 binding to the MTs.
  • the VP22 protein or fragment thereof can be coupled to the coupling partner by chemical or recombinant DNA techniques.
  • the coupling partner substance where it is a polypeptide, can preferably be expressed as a fusion with the VP22.
  • Preferred embodiments include fusion proteins each resulting from expression in a recombinant host cell of a polynucleotide sequence of which part encodes part of all of the amino acid sequence of the VP22 protein and another part encodes part or all of the amino acid sequence of a coupling partner polypeptide.
  • the nucleic acid encoding the fusion protein only needs to be transfected into a portion of cells in a population as the VP22 fusion is secreted and taken up into untransfected cells.
  • its expression can be controlled using tissue specific or inducible promoters.
  • the VP22 and the substance can be covalently coupled or non covalently associated, e.g. using lipid based vehicles, and directly exposed to the target cells.
  • this allows non peptidyl molecules, such as nucleic acid, drugs or markers (in addition to or as alternatives to proteins) to be associated with VP22 and be taken up into a population of cells, without the need to express the VP22 and the associated molecule in at least a part of the population of cells to which delivery of the VP22 and/or the associated molecule is desired.
  • the partner can be coupled by chemical crosslinking, in per se known manner, e.g. by standard techniques involving covalent attachment for example to exposed tyrosine residues of the VP22 protein or to the epsilon-amino groups of lysine residues or the carboxyl groups of aspartate and glutamate residues.
  • the present invention provides VP22 variants having a transport property associated with full length VP22, but which are substantially incapable of binding to microtubules.
  • These VP22 variants can be based on the insertion, addition, deletion or substitution of one or more amino acids in the region of VP22 corresponding to amino acid residues 119 to 192 to reduce or eliminate VP22 binding to microtubules, while retaining another biological activity of VP22 such as the transport property.
  • One such example with much reduced MT binding is provided by e.g. a VP22 deletant in respect of aminoacids 160-173 of VP22 of HSV1,
  • Other examples can also be provided by varying the amino acid sequence of the VP22 protein, e.g.
  • VP22 variants can be engineered to reduce or eliminate the MT binding activity by modification elsewhere in the molecule, where such modification results in the disruption of the determinant of VP22 responsible for MT binding.
  • binding of the protein to MTs prevents this portion of the VP22 from being secreted and serving as a transport protein, e.g. where the VP22 is expressed as a fusion with a protein for delivery to other cells. Accordingly, engineering variants of VP22 that lack the MT binding property, but which retain the transport property can be usefully employed to improve the efficiency of the transport, where MT binding is not required.
  • the present invention provides the use of VP22 variants as defined above as transport proteins, in ways analogous to the uses and properties of VP22 out in application WO97/05265.
  • FIG. 1 shows the localisation patterns of VP22 and MTs obtained using COS-1 cells expressing VP22 as compared with untransfected cells.
  • the localisation patterns were produced by immunofluorescence using anti alpha-tubulin and VP22 antibodies.
  • FIGS. 1 c and 1 d show the effect of adding taxol to the COS-1 cells expressing VP22 as compared to untransfected cells.
  • FIG. 2 shows the localisation patterns obtained using immunofluorescence with anti-alpha-tubulin antibody in a COS-1 cell line expressing VP22 and a control.
  • FIGS. 2 c and 2 d show the effect of nocodazole to the VP22 cell line and the control.
  • FIG. 3 a shows schematically a series of C-terminal deletion mutants of VP22 which were transfected in COS-1 cells and their ability to bundle MT determined.
  • FIGS. 3 b - 3 e show the localisation patterns obtained using immunofluorescence to assess MT bundling.
  • An active portion of the VP22 polypeptide means, in the context of those parts of this specification in which proteins having microtubule-binding functionality are of concnern, a peptide that comprises less than the full length sequence of VP22 (and optionally comprises further sequence, e.g. not derived from the sequence of VP22 but from the sequence of a polypeptide fusion protein coupling partner) but which retains a property of binding to microtubules.
  • Derivatives of VP22 polypeptides considered within the scope of thois specificaiton include polypeptides modified by varying the amino acid sequence of the VP22 protein, e.g. by manipulation of the nucleic acid encoding the protein or by altering the protein itself after it has been synthesised. Such derivatives of the natural amino acid sequence can involve insertion, addition, deletion or substitution of one or more amino acids.
  • VP22 polypeptides which are derivatives or sequence variants will generally have greater than about 70% sequence homology with the amino acid sequence of a wild type VP22 sequence, e.g. that of HSV1, and preferably shares greater than about 80%, greater than about 90% or greater than about 95% sequence homology.
  • Particular amino acid sequence variants can differ by insertion, addition, substitution or deletion e.g. of 1 amino acid, 2, 3, 4, 5 10, 10 20 20 30, 30 50, 50 100, 100 150, or more than 150 amino acids.
  • the variants considered within the scope of the present specification include those with conservative alterations in the VP22 amino acid sequence, i.e. with alterations resulting in residues having similar charge and/or structure at the position or positions being altered. Typically, conservative alteration does not in itself fundamentally alter a biological activity of VP22 protein, e.g. MT binding activity.
  • variants considered within the scope of the present specification also include those with non-conservative alterations, i.e. alterations resulting in residues having substantially different charge and/or structure at the positions being altered.
  • Non conservative alterations can be made to change a biological activity of the protein, e.g. to abolish a given activity (e.g. MT binding) or provide a biological activity that is substantially absent from the starting protein.
  • amino acid classes considered in the foregoing discussion comprise two main groups, charged and uncharged, and each of these groups is divided into subgroups, usually considered to be as follows:
  • basic residues are lysine, arginine, and histidine.
  • Acidic residues are aspartic acid, and glutamic acid.
  • uncharged amino acids are hydrophilic residues glutamine, serine, threonine, and asparagine, and aliphatic residues alanine, glycine, valine, leucine, and isoleucine; as well as non polar residues cysteine, methionine, and proline, and aromatic residues phenylalanine, tyrosine, and tryptophan.
  • the biological property of binding to MTs can be determined using antibodies against VP22, or the active portion or derivative, and commercially available anti alpha- or beta-tubulin antibodies.
  • labelling the antibodies e.g. using immunofluorescence
  • comparing the patterns obtained when the antibodies bind to the cells in the test makes it possible to determine whether the antibodies are co localised in the cells.
  • a fusion between VP22 and green fluoresecent protein (GFP), as described in WO 97/05265, is also, like wild-type VP22 protein, capable of stabilising MTs, thus allowing convenient fluorescence monitoring procedures including fluorecence microscopy to monitor the MT stabilisation and its effects.
  • GFP green fluoresecent protein
  • the peptide determinant of VP22 responsible for MT binding can be further refined using and adapting techniques well known per se in the art. This can be done by systematically varying the amino acid residues in the peptide, e.g. by substituting each residue in turn. These parts or residues constituting the active region of the compound are known as its pharmacophore.
  • alanine scans take peptide fragments from a region of the full length protein associated with a biological activity and replace the amino acids with alanine. If the substitution of a given residue for alanine reduces or eliminates the biological activity, it shows that residue is important or critical for that biological activity. Repeating this helps to define the amino acids that are responsible, e.g. for the MT binding of VP22.
  • Other techniques that can be used to resolve motif in VP22 protein include deletion series, site directed mutagenesis, and yeast two-hybrid screening.
  • the VP22 proteins of the invention can be formulated in pharmaceutical compositions.
  • the compositions can comprise, in addition to one of the above VP22 proteins, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non toxic and should not interfere with the efficacy of the active ingredient.
  • a pharmaceutically acceptable excipient e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.
  • compositions for oral administration can be in tablet, capsule, powder or liquid form.
  • a tablet can include a solid carrier such as gelatin or an adjuvant.
  • Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol can be included.
  • the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen free and has suitable pH, isotonicity and stability.
  • a parenterally acceptable aqueous solution which is pyrogen free and has suitable pH, isotonicity and stability.
  • isotonic vehicles such as sodium chloride injection, Ringer's injection, lactated Ringer's Injection.
  • Preservatives, stabilisers, buffers, antioxidants and/or other additives can be included, as desired.
  • compositions provided and used according to the present invention are given to an individual subject of treatment, administration is preferably in a prophylactically effective amount or a therapeutically effective amount (as the case may be, prophylaxis can be considered therapy), this being sufficient to show benefit to the individual.
  • the actual amount administered, and rate and time course of administration depends on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of medical practitioners and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of techniques and protocols as mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980.
  • a composition can be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
  • VP22 binds to microtubules in COS 1 cells.
  • MTs are polymers of heterodimers composed of alpha and beta tubulin. They form networks within the cytoplasm and perform several functions for the cell, including the trafficking of organelles and vesicles; the movement of chromosomes during mitosis; and the general organisation of the cytoplasm and maintenance of cell architecture.
  • MTs are dynamic structures, which grow from a central MT organising centre (MTOC) out towards the periphery of the cell. These dynamics are important during cell division when the MTs depolymerise to form the spindle poles. As such, inhibition of MT depolymerisation can lead to retarded cell division.
  • MTOC MT organising centre
  • COS 1 cells were transfected with the VP22 expression plasmid pGE109. Forty hours after transfection, the cells were fixed with 100% methanol and double immunofluorescence carried out with antibodies against VP22 (polyclonal AGV30) and alpha tubulin (monoclonal anti alpha tubulin, Sigma).
  • Untransfected cells labelled in the same manner exhibited the typical localisation pattern for MTs (FIG. 1 a ) with the MT network radiating from the MTOC.
  • cells expressing VP22 had a very different MT pattern where the tubules were bundled and co localised with the VP22 filaments (FIG. 1 b ).
  • COS 1 cells treated in the same manner were exposed to the MT stabilising drug taxol (10 microM) for 30 minutes prior to fixation.
  • taxol has the effect of creating large bundles of MTs (FIG. 1 c ).
  • VP22 expressing cells these bundles were even more striking and again co-localised with VP22 (FIG. 1 d ).
  • VP22 colocalises and reorganises the cellular MT network into bundles.
  • the MT binding property of VP22 can also be used to deliver coupling products between VP22 and other substances, such as taxol or a related compound to MTs.
  • VP22 stabilises microtubules against depolymerising agents.
  • MTs When MTs are bundled as observed above, they are often stabilised against depolymerising agents.
  • VP22 bundling of MTs also stabilises these filaments, COS 1 cells were transfected as before, and then exposed to the drug nocodazole (500 ng/ml), an agent known to depolymerise MTS, for 30 minutes prior to fixation. The cells were then fixed and processed for immunofluorescence using only the anti alpha tubulin antibody.
  • VP22 can stabilise MTs against depolymerising agents. The same effect was seen upon incubation of cells at 4 deg C., a treatment which destabilises MTs. In this case VP22 also stabilised MTs against depolymerisation by 4 deg C. incubation. The stabilisation of MTs by VP22 makes it possible to use VP22 proteins in applications such as retarding the growth of cells, e.g. in the treatment of proliferative disorders.
  • a fusion between VP22 and green fluoresecent protein (GFP), as described in WO 97/05265, is also, like wild-type VP22 protein, capable of stabilising MTs, thus allowing convenient fluorescence monitoring procedures including fluorecence microscopy to monitor the MT stabilisation and its effects.
  • GFP green fluoresecent protein
  • the plasmids encoding WT, del-267, del-192 and del-119 (FIG. 3 a ) forms of VP 22 were transfected into COS 1 cells and analysed by immunofluorescence using the anti VP22 antibody AGV30.
  • the del-267 and del-119 constructs comprise respectively aminoacids 1-267 inclusive, and aminoacids 1-119 inclusive of the wild type sequence of VP22 of HSV1 as disclosed in above-cited WO 97/05265 and references cited therein.
  • the del-192 construct consists of aminoacids 1-191 inclusive plus a residue 192 mutated to leucine.
  • WT gave the typical localisation pattern of a central cell with VP22 in cytoplasmic filaments, surrounded by cells with VP22 in their nuclei (FIG. 3 b ). While the del-267 mutant did not have the ability to move between cells (see previous patent applications), it still retained the property of MT bundling (FIG. 3 c ).
  • del-192 was also capable of bundling MTs (FIG. 3 d ), although it was not as efficient as either WT or del-267.
  • removal of a further 73 residues from the C terminus of VP22 resulted in a protein which localised in a cytoplasmic diffuse pattern and which did not form cytoplasmic filaments (FIG. 3 e ).
  • variant VP22 proteins consisting of residues 1-172 of the native VP22 of HSV1, or of residues 1-192 (with aa192 modified to leucine), or 1-267, retain in some degree the ability to bundle microtubules as decribed herein. In these examples the longer sequences have increasing efficiency. It was also found that the VP22 fragments consisting of 1-119 or 1-159 did not appear to retain the MT-bundling activity. A mutant with a regional deletion of residues 160-173 and in their place three ‘spacer’ residues his, gly and pro was found to have substantially reduced effectiveness of MT binding.
  • homologues of herpesviral VP22 that can be used in the present invention are for example the homologues of HSV1-VP22 in other herpesviruses such as HSV type 2 (HSV2), bovine herpesvirus (BHV), and Marek's disease virus (MDV), and the derivatives of such homologues analogous to the derivatives discussed above.
  • HSV2 HSV type 2
  • BHV bovine herpesvirus
  • MDV Marek's disease virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
US09/381,211 1997-03-21 1998-03-23 Vp22 proteins and uses thereof Abandoned US20020128174A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/617,910 US7067632B2 (en) 1997-03-21 2003-07-10 VP22 proteins and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9705903.4 1997-03-21
GBGB9705903.4A GB9705903D0 (en) 1997-03-21 1997-03-21 VP22 Proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/617,910 Continuation US7067632B2 (en) 1997-03-21 2003-07-10 VP22 proteins and uses thereof

Publications (1)

Publication Number Publication Date
US20020128174A1 true US20020128174A1 (en) 2002-09-12

Family

ID=10809645

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/381,211 Abandoned US20020128174A1 (en) 1997-03-21 1998-03-23 Vp22 proteins and uses thereof
US10/617,910 Expired - Fee Related US7067632B2 (en) 1997-03-21 2003-07-10 VP22 proteins and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/617,910 Expired - Fee Related US7067632B2 (en) 1997-03-21 2003-07-10 VP22 proteins and uses thereof

Country Status (7)

Country Link
US (2) US20020128174A1 (https=)
EP (1) EP0971953A1 (https=)
JP (1) JP2001520521A (https=)
AU (1) AU6739398A (https=)
CA (1) CA2283794A1 (https=)
GB (1) GB9705903D0 (https=)
WO (1) WO1998042742A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423334B1 (en) 1997-10-01 2002-07-23 Elan Corporation, Plc Composition and method for enhancing transport across gastrointestinal tract cell layers
GB9816761D0 (en) 1998-07-31 1998-09-30 Phogen Limited Herpesvirus preparations and their uses
DE60040274D1 (de) * 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
US6358739B1 (en) 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
US6451601B1 (en) 1999-04-12 2002-09-17 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
GB9930519D0 (en) * 1999-12-24 2000-02-16 Phogen Limited Uses of transport proteins
US6688084B2 (en) * 2000-03-24 2004-02-10 International Paper Company Automated bulk box strapper
BRPI0406647A (pt) * 2003-01-06 2005-12-06 Angiochem Inc Método para transportar um composto através da barreira sanguìnea do cérebro
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
TR201905480T4 (tr) 2008-04-18 2019-05-21 Angiochem Inc Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri.
MX2011004019A (es) 2008-10-15 2011-06-24 Angiochem Inc Conjugados de etoposido y doxorubicina para entrega de farmacos.
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
WO2010069074A1 (en) 2008-12-17 2010-06-24 Universite Du Quebec A Montreal Membrane type-1 matrix metalloprotein inhibitors and uses thereof
WO2010121379A1 (en) 2009-04-20 2010-10-28 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
AU2010268726A1 (en) 2009-07-02 2012-01-19 Angiochem Inc. Multimeric peptide conjugates and uses thereof
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5278324A (en) 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5059699A (en) 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
TW223634B (https=) 1991-03-18 1994-05-11 Kingston David G I
FR2679230B1 (fr) 1991-07-16 1993-11-19 Rhone Poulenc Rorer Sa Nouveaux derives d'analogues du taxol, leur preparation et les compositions qui les contiennent.
CA2128693A1 (en) 1992-01-31 1993-08-05 Peter B. Schiff Taxol as a radiation sensitizer
US5272171A (en) 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5631278A (en) 1992-12-02 1997-05-20 Thomas Jefferson University Methods of killing protozoal parasites
US5356927A (en) 1992-12-02 1994-10-18 Thomas Jefferson University Methods of treating plasmodium and babesia parasitic infections
US5583153A (en) * 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
BR9610058A (pt) * 1995-07-28 1999-07-27 Marie Curie Cancer Care Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses

Also Published As

Publication number Publication date
US7067632B2 (en) 2006-06-27
JP2001520521A (ja) 2001-10-30
EP0971953A1 (en) 2000-01-19
US20050118717A1 (en) 2005-06-02
CA2283794A1 (en) 1998-10-01
GB9705903D0 (en) 1997-05-07
WO1998042742A1 (en) 1998-10-01
AU6739398A (en) 1998-10-20

Similar Documents

Publication Publication Date Title
US7067632B2 (en) VP22 proteins and uses thereof
US20250082778A1 (en) Rna guided eradication of human jc virus and other polyomaviruses
CN1208438A (zh) 转运蛋白及其应用
JP2019512458A (ja) Ｒｎａによって誘導された、ヒトｊｃウイルス及び他のポリオーマウイルスの根絶
JP2001508304A (ja) 細胞内及び細胞間輸送のための融合タンパク質、並びにその使用
LaVail et al. Viral regulation of the long distance axonal transport of herpes simplex virus nucleocapsid
Bultmann et al. Modified FGF4 signal peptide inhibits entry of herpes simplex virus type 1
US8012925B2 (en) Agent for inducing apoptosis comprising MSX1 or a gene encoding the same as an active ingredient
Lee et al. Gene delivery using a receptor‐mediated gene transfer system targeted to hepatocellular carcinoma cells
CA2395575A1 (en) Uses of transport proteins for controlling cell cycle
US20060210536A1 (en) Methods and compositions for inhibiting stat signaling pathways
AU783081B2 (en) VP22 proteins and uses thereof
EP1549339B1 (en) Targeting of herpes simplex virus to specific receptors
US8765666B2 (en) Adenovirus dodecahedron particles for delivery of pharmaceutical agents
WO1998013508A1 (en) Method of targeting malignant cells using an e2f responsive promoter
WO1998013508A9 (en) Method of targeting malignant cells using an e2f responsive promoter
MXPA99008620A (en) Vp22 proteins and uses thereof
EP1290017A2 (en) Compositions and methods for delivery of a molecule into a cell
US11155582B2 (en) Antiviral peptide and use thereof
Zavaglia et al. Poor intercellular transport and absence of enhanced antiproliferative activity after non‐viral gene transfer of VP22‐P53 or P53‐VP22 fusions into p53 null cell lines in vitro or in vivo
US5847083A (en) Modified p53 constructs which enhance DNA binding
US11767345B2 (en) Antiviral peptide and use thereof
US7105156B1 (en) Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells
WO1998047919A1 (en) Materials and methods relating to stabilising substances in cells
KR100279797B1 (ko) 세포 주기 조절 조성물 및 그의 사용 방법

Legal Events

Date Code Title Description
AS Assignment

Owner name: PHOGEN LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ELLIOTT, GILLIAN DAPHNE;REEL/FRAME:010361/0297

Effective date: 19990818

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION